NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT04105062 2021-12-09
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT01923233 2020-01-22
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT01995227 2020-01-22
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT02261844 2017-03-30
Resveratrol and Human Hepatocyte Function in Cancer
University of Louisville
Phase 1/2 Withdrawn
NCT00244348 2015-08-27
Hepatic Artery Infusion With Oxaliplatin
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT00093548 2012-10-04
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn